The WACC of Enlie Pharmaceutical JSC (BCP.VN) is 10.8%.
| Range | Selected | |
| Cost of equity | 8.50% - 10.70% | 9.60% |
| Tax rate | 0.10% - 1.00% | 0.55% |
| Cost of debt | 11.90% - 14.50% | 13.20% |
| WACC | 9.7% - 11.9% | 10.8% |
| Category | Low | High |
| Long-term bond rate | 2.7% | 3.2% |
| Equity market risk premium | 9.5% | 10.5% |
| Adjusted beta | 0.61 | 0.66 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 8.50% | 10.70% |
| Tax rate | 0.10% | 1.00% |
| Debt/Equity ratio | 0.51 | 0.51 |
| Cost of debt | 11.90% | 14.50% |
| After-tax WACC | 9.7% | 11.9% |
| Selected WACC | 10.8% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for BCP.VN:
cost_of_equity (9.60%) = risk_free_rate (2.95%) + equity_risk_premium (10.00%) * adjusted_beta (0.61) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.